These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 15307286)
1. [The opinion about the reimbursement mechanism for psychotropic drugs for mental disorders]. Puzyński S Psychiatr Pol; 2004; 38(2):200-2. PubMed ID: 15307286 [No Abstract] [Full Text] [Related]
2. [Guiding principles for the interpretation of reimbursement categories applicable in definite indications of psychiatric drugs]. Bánki CM Psychiatr Hung; 2007; 22(1):82-8. PubMed ID: 17642122 [No Abstract] [Full Text] [Related]
3. [Generics in psychiatry--do they have the same therapeutic equivalence as the original?]. Kasper S; Lentner S Neuropsychiatr; 2008; 22(4):221-2. PubMed ID: 19080992 [No Abstract] [Full Text] [Related]
4. Mental health in the Medicare Part D drug benefit: a new regulatory model? Donohue J Health Aff (Millwood); 2006; 25(3):707-19. PubMed ID: 16684735 [TBL] [Abstract][Full Text] [Related]
5. Overview: pharmacogenomics of psychiatric disorders--separating the dreams from the realities. Briley M; Moret C Curr Opin Investig Drugs; 2001 Aug; 2(8):1105-7. PubMed ID: 11892921 [No Abstract] [Full Text] [Related]
6. [Clinical testing of new psychopharmaceuticals]. Helmchen H; Müller-Oerlinghausen B Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1978; 19():7-26. PubMed ID: 362172 [No Abstract] [Full Text] [Related]
7. Riding the biological brain wave. Stavig V Minn Med; 1996 Jan; 79(1):14-8. PubMed ID: 8587554 [No Abstract] [Full Text] [Related]
8. Making an investment in psychotropic drugs. Wainscott C Behav Healthc Tomorrow; 1999 Apr; 8(2):36-7. PubMed ID: 10351299 [No Abstract] [Full Text] [Related]
9. Improving drug safety and tolerability in psychiatric clinical practice. Haddad PM; Dursun SM Hum Psychopharmacol; 2008 Jan; 23 Suppl 1():S1-2. PubMed ID: 18098219 [No Abstract] [Full Text] [Related]
11. Implications of Part D for mentally ill dual eligibles: a challenge for Medicare. Morden NE; Garrison LP Health Aff (Millwood); 2006; 25(2):491-500. PubMed ID: 16522603 [TBL] [Abstract][Full Text] [Related]
12. Potential cost savings from pill splitting of newer psychotropic medications. Cohen CI; Cohen SI Psychiatr Serv; 2000 Apr; 51(4):527-9. PubMed ID: 10737832 [TBL] [Abstract][Full Text] [Related]
14. [Reaction to 'Bitter and gilded pills: psychiatry in the light (or shadow) of the pharmaceutical industry' and to 'The importance of public-private cooperation. Comment on Vandereycken']. Buis WM Tijdschr Psychiatr; 2006; 48(6):500-1; author reply 501-3. PubMed ID: 16956013 [No Abstract] [Full Text] [Related]
15. Improving mental health treatments through comparative effectiveness research. Wang PS; Ulbricht CM; Schoenbaum M Health Aff (Millwood); 2009; 28(3):783-91. PubMed ID: 19414887 [TBL] [Abstract][Full Text] [Related]
16. Elderly people with mental disorders: experiencing the use of psychotropic medicines. Marin MJS; Maftum MA; Lacerda MR Rev Bras Enferm; 2018; 71 Suppl 2():835-843. PubMed ID: 29791635 [TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic and pharmacokinetic interactions of psychotropic drugs with antiepileptic drugs. Kanner AM; Gidal BE Int Rev Neurobiol; 2008; 83():397-416. PubMed ID: 18929094 [TBL] [Abstract][Full Text] [Related]
18. Prescribing practices of psychiatrists and primary care physicians caring for children with mental illness. Harpaz-Rotem I; Rosenheck RA Child Care Health Dev; 2006 Mar; 32(2):225-37. PubMed ID: 16441857 [TBL] [Abstract][Full Text] [Related]
19. Medicaid policy changes in mental health care and their effect on mental health outcomes. Cuellar AE; Markowitz S Health Econ Policy Law; 2007 Jan; 2(Pt 1):23-49. PubMed ID: 18634670 [TBL] [Abstract][Full Text] [Related]
20. Prescription drugs and the changing patterns of treatment for mental disorders, 1996-2001. Zuvekas SH Health Aff (Millwood); 2005; 24(1):195-205. PubMed ID: 15647230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]